APYX trades 46.0% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes APYX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Apyx Medical Corporation (APYX) has a Wall Street consensus price target of $6.00, based on estimates from 9 covering analysts. With the stock currently trading at $4.01, this represents a potential upside of +46.0%. The company has a market capitalization of $168M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, APYX trades at a trailing P/E of -14.9x. Analysts expect EPS to grow -28.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SSKNSTRATA Skin Sciences, Inc. | $712472 | $0.12 | — | — | — | — | — |
ARAYAccuray Incorporated | $37M | $0.31 | — | — | — | — | — |
INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
AEYEAudioEye, Inc. | $76M | $6.08 | — | — | — | — | — |
INMDInMode Ltd. | $837M | $13.21 | $18.00 | +34.3% | Hold | 10.0x | 11 |
LNTHLantheus Holdings, Inc. | $6.9B | $106.13 | $108.50 | +4.5% | Buy | 19.4x | 17 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
BSXBoston Scientific Corporation | $65.9B | $44.33 | $82.90 | +83.0% | Buy | 13.5x | 44 |
ABTAbbott Laboratories | $152.6B | $87.78 | $127.46 | +44.2% | Buy | 16.1x | 41 |
Quick answers to the most common questions about buying APYX stock.
The consensus Wall Street price target for APYX is $6, representing 46.0% upside from the current price of $4.01. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
APYX has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies 46.0% upside from current levels.
APYX's current price is $4.01 with a consensus target of $6 (46.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for APYX, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
APYX is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month APYX stock forecast based on 9 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on APYX, with a "Buy" consensus rating and $6 price target (46.0% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
APYX analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.